Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Form 424B3 CANTOR FITZGERALD INFRAS
-
Form 424B3 CANTOR FITZGERALD INFRAS
-
Complete Solar to Present at Cantor Fitzgerald Technology Conference, March 11, 2025, in New York
-
Cantor Fitzgerald Reiterates Overweight Rating on AxoGen, Inc. (AXGN)
-
Cantor Fitzgerald Reiterates Overweight Rating on Disc Medicine (IRON)
-
NeuroPace Inc (NPCE) PT Raised to $20 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Neutral Rating on Rigel Pharmaceuticals (RIGL)
-
Cantor Fitzgerald Reiterates Overweight Rating on CrowdStrike Holdings (CRWD)
-
Cantor Fitzgerald Reiterates Overweight Rating on EVgo, Inc. (EVGO)
-
ICF to Present at the 2025 Cantor Fitzgerald Global Technology Conference
-
Y-mAbs Therapeutics (YMAB) PT Lowered to $19 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
-
Cantor Fitzgerald Reiterates Overweight Rating on ADMA Biologics (ADMA)
-
Riot Platforms (RIOT) Reports February 2025 Production and Operations Updates
-
Domo to Participate in the 2025 Cantor Fitzgerald Global Technology Conference
-
Riot Announces February 2025 Production and Operations Updates
-
Cantor Fitzgerald Reiterates Overweight Rating on AST Spacemobile (ASTS)
-
Cantor Fitzgerald Reiterates Overweight Rating on GitLab Inc (GTLB)
-
Bitfarms Announces Participation in Upcoming Investor and Industry Conferences
-
Cantor Fitzgerald Reinstates Pliant Therapeutics (PLRX) at Neutral
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
BlackSky to Participate at Two Upcoming Investor Conferences
-
Fifth Era Acquisition Corp I Completes $230,000,000 Initial Public Offering
-
Cantor Fitzgerald Reiterates Overweight Rating on TG Therapeutics (TGTX)
-
Form NPORT-P CANTOR FITZGERALD INFRAS For: Dec 31
-
SEI Launches Alternative Investment Product Marketplace, Expands Access to Private Markets
-
Cantor Fitzgerald and Silverstein Properties Close Opportunity Zone Fund with more than $470 Million of Capital Raised
-
Cantor Fitzgerald Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
-
Cantor Fitzgerald Reiterates Overweight Rating on Jasper Therapeutics (JSPR)
-
Cantor Fitzgerald Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Marvell (MRVL)
-
Cantor Fitzgerald Reiterates Overweight Rating on Broadcom Limited (AVGO)
-
Cantor Fitzgerald Reiterates Overweight Rating on 89bio Inc. (ETNB)
-
Cantor Fitzgerald Reiterates Overweight Rating on Archer Aviation Inc. (ACHR)
-
Bitfarms Provides February 2025 Production and Operations Update
-
MoneyShow Investment Masters Symposium to feature Craig O'Sullivan as guest speaker along with Jim Bianco, Dan Ives, Tom Lee, Kathryn Vera, and Ed Yardeni
-
How Kamada (NASDAQ: KMDA) Is Transforming Its Strategic Focus Into Commercial Growth
-
Nlight (LASR) PT Lowered to $14 at Cantor Fitzgerald
-
Progyny (PGNY) PT Raised to $26 at Cantor Fitzgerald
-
Nerdy (NRDY) PT Raised to $1.50 at Cantor Fitzgerald
-
DocGo (DCGO) PT Lowered to $4 at Cantor Fitzgerald
-
CrowdStrike Holdings (CRWD) PT Raised to $440 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Avidity Biosciences (RNA)
-
Cantor Fitzgerald Reiterates Overweight Rating on PureCycle Technolgies (PCT)
-
Crinetics (CRNX) PT Raised to $100 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on 89bio Inc. (ETNB)
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $50 at Cantor Fitzgerald
-
Oranogenesis Holdings (ORGO) PT Raised to $6 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Janux Therapeutics (JANX)

